Allworth Financial LP Makes New Investment in Medpace Holdings, Inc. $MEDP

Key Points

• Allworth Financial acquired 3,894 Medpace shares worth approximately $2.06 million in the second quarter, while institutional investors and hedge funds collectively own 77.98% of the company.
• Medpace exceeded quarterly expectations, reporting $4.25 in EPS versus $3.98 expected and $707.33 million in revenue, up 17.2% year over year. The company issued fiscal 2026 EPS guidance of $17.25–$17.95.
• Analysts maintain a consensus “Hold” rating with an average price target of $584.18, below the stock’s reported $620.75 price; insiders sold 122,261 shares worth about $71.7 million over the past quarter.

Allworth Financial LP acquired a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 3,894 shares of the company's stock, valued at approximately $2,062,000.

A number of other hedge funds also recently made changes to their positions in the business. BlackRock Inc. bought a new position in Medpace during the second quarter worth $1,323,047,000. AQR Capital Management LLC raised its position in shares of Medpace by 65.1% in the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company's stock valued at $518,170,000 after purchasing an additional 404,226 shares during the period. Madison Asset Management LLC bought a new position in shares of Medpace in the second quarter valued at about $128,956,000. Arrowstreet Capital Limited Partnership lifted its stake in shares of Medpace by 205.8% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company's stock worth $161,523,000 after buying an additional 211,411 shares during the last quarter. Finally, Franklin Resources Inc. lifted its stake in shares of Medpace by 158.6% during the 4th quarter. Franklin Resources Inc. now owns 299,472 shares of the company's stock worth $168,198,000 after buying an additional 183,645 shares during the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. TD Cowen upped their price target on shares of Medpace from $419.00 to $492.00 and gave the company a "hold" rating in a research note on Friday, July 24th. Royal Bank Of Canada upped their target price on Medpace from $484.00 to $692.00 and gave the company an "outperform" rating in a research report on Friday, July 24th. Leerink Partners set a $620.00 target price on Medpace in a research note on Thursday, July 23rd. Wall Street Zen cut Medpace from a "buy" rating to a "hold" rating in a report on Saturday, April 25th. Finally, Mizuho lifted their price target on Medpace from $586.00 to $665.00 and gave the stock an "outperform" rating in a report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $584.18.

Insider Buying and Selling at Medpace

In related news, Director Fred B. Davenport, Jr. sold 7,283 shares of Medpace stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $606.15, for a total transaction of $4,414,590.45. Following the sale, the director directly owned 3,798 shares in the company, valued at $2,302,157.70. This trade represents a 65.73% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Brian T. Carley sold 5,000 shares of the business's stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the sale, the director directly owned 27,825 shares in the company, valued at $16,935,129.75. The trade was a 15.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 122,261 shares of company stock worth $71,729,129 over the last quarter. Insiders own 20.50% of the company's stock.

Medpace Stock Performance

Shares of NASDAQ:MEDP opened at $620.75 on Friday. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90. The company has a market capitalization of $17.33 billion, a PE ratio of 36.39, a price-to-earnings-growth ratio of 2.73 and a beta of 1.15. The company has a fifty day moving average of $550.16 and a 200-day moving average of $492.71.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. During the same quarter last year, the business posted $3.10 EPS. Medpace's revenue for the quarter was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source